Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide plus MesoCancerVac in mesothelioma
NL-OMON32554Phase 1Recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2009
- Modality
- Small Molecules, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cyclophosphamide and MesoCancerVac in mesothelioma, sponsored by Erasmus MC. Primary endpoint: Safety and toxicity. Started Jan 2009; status: recruiting.
02
Drugs
cyclophosphamideMesoCancerVac
03
Conditions
mesothelioma
Beyond the preview
Go deeper on NL-OMON32554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32554.